Sunday, February 07, 2016 11:03:12 PM
Rule:
- weight: interim announcement (DMC recommendation) - 40% (w1) / Eff% - 40% (w2) / interim event -20% (w3) (if interim event date won't be available: 50-50%)
- difference in days (interim announcement (DMC recommendation) - d1 - and interim event - d3)
- difference in percentage 2 digits, eg. 1.15% (Eff% - d2)
- no data = 100 difference for a category
- d1 x w1+ d2 x w2 (+d3 x w3) = score
- lowest score will win
Feel free to correct or join till update from the Co. (Don't have to guess all, but please keep the order. ie.: June 12 / 25% / na or June 12 / 25% / April 24.)
(FYI: I f no exact date, I used the middle of te period)
- ziploc_1: na / Jan 1 (Q4-Q1) / na / na
- - - - - - - - - - - - - - - - - - - - - - - - - -
- gozips: stop / Feb 15 (Feb) / 35% / Dec
- marzan: stop / Feb 24 / 33% / na
- isaeed: cont. / March 15 / na / January 15 (no stop @ interim due to 23-25% eff.)
- Mogwai: cont. / March 15 (mid March) / na / early February (no stop @ interim)
- James364202: stop / March 15 (Spring - March) / 45% (40-50%, 50-60% low HDL, high trigs subgroup) / na
- goamrn: stop / April 1 / 31% / February 14
- chas1232123: stop / April 1 / 33% / February 11 (plus or minus a month)
- rydad21: stop / April 1 / na / na
- xblkbk: stop / April 5 / 34% / na
- Hspooner: stop / April 8 /33% / February 15
- Invest83838: stop / April 15 / 39.6% / February 14
- Pharmacydude: stop / April 22 / 35% / February 29
- Biofalcon: stop / April 26 / 29% / February 16
- jessellivermore: stop / May Day / 37.5% (35-40%) / na
- golf stud: stop / May 5 / 40.5% / March 18
- annac: stop / May 7 / 27% / March 7
- rafunrafun: stop / May 7 / 38% / February 11 (placebo 5.5%)
- Sam81: stop / May 15 (May) / 27% (>27%) / March 11-12
- drrc1949: stop / May 15 (May) / 34% / February 27
- Squeck: stop / May 15 / 45% / March 31
- invest2992: Stop / May 15 / 50% / March 30
- HDGabor: - stop / May 17 (depends on analysis duration, so April-June) / 36% (30-40%) / Feb 24 (2nd half of February)
- FishyFingers: stop / May 18 / 57% (>50%) / March 17
- heysfguy: stop / May 24 / 33% / Feb 2
- Danouse: stop / May 27 / 27% / March 29
- alwayswatching1: stop / May 27 / 41% / na
- Nukemtiltheyglow: stop / May 31 (May-June) / 45% / na
- slowmover: June 8 / 32% / March 3
- mrmainstreet: stop / June 15 (June) / 25% / March
- Repero: stop / June 15 (June) / 29% / March
- oneragman: June 15 (June) / 31% / April 10
- lbwagain: stop / June 15 (mid June) / 34.5% (33-36%) / April 23
- Biobillionair: stop / June 15 (June) / 40% / February 23 (Placebo Rate 5.6% V Event Rate 3.36%)
- Louieblouie: stop / June 17 / 27% / April 30
- Benny7459: stop / June 21 / 42% / April 21
- PghKid1 (from ST): stop / June 22 (June 15-30) / 31% / March 1-15
- Albino2: stop / June 28 (last week of June) / 51% / April 8
- BioChica: stop / June 30 (end of June) / 40% (>30% / 35-45%) / May 23
- rosemountbomber: stop / July 1 / 33% / na
- zumantu: stop / August 8 / 32% / April 18
- CaptBeer: stop / September 1 / 43% / June 1
- Whalatane: cont. / September 30 / 20% / June 30
Best,
G
#STRONGERTOGETHER
Disclosure: I am long with this stock. I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for it.
Recent AMRN News
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM